泼尼松龙醋酸戊酸酯 | 72064-79-0

• 物质功能分类: 有机原料 - 羧酸类化合物及衍生物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 类固醇和类固醇衍生物
• 中文名称: 泼尼松龙醋酸戊酸酯
• 中文别名: 泼尼瓦酯；泼尼松龙戊酸酯
• 英文名称: Prednisolone valerate acetate
• 英文别名: [(8S,9S,10R,11S,13S,14S,17R)-17-(2-acetyloxyacetyl)-11-hydroxy-10,13-dimethyl-3-oxo-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-17-yl] pentanoate
• CAS: 72064-79-0
• 化学式: C₂₈H₃₈O₇
• 分子量: 486.6
• InChiKey: DGYSDXLCLKPUBR-SLPNHVECSA-N

物化性质

• 沸点：
  502.49°C (rough estimate)
• 密度：
  1.1134 (rough estimate)
• 溶解度：
  可溶于氯仿（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  35
• 可旋转键数：
  9
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.71
• 拓扑面积：
  107
• 氢给体数：
  1
• 氢受体数：
  7

制备方法与用途

类别：有毒物品

• 毒性分级：中毒
• 急性毒性：腹腔注射-小鼠 LD50: 1360 毫克/公斤
• 可燃性危险特性：可燃
• 储运特性：库房通风、低温干燥
• 灭火剂：干粉、泡沫、砂土和水

文献信息

• [EN] NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES<br/>[FR] NOUVEAUX DÉRIVÉS DE PHTALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE
  申请人：NYCOMED GMBH

  公开号：WO2012171900A1

  公开（公告）日：2012-12-20

  The compounds of formula (1), in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and 5 phosphodiesterase.

  式（1）中的化合物，其中R1、R7、R8、R9、R10、R17、R18、R19、R20和m的含义如描述中所述，是新颖的有效的4型和5型磷酸二酯酶抑制剂。
• NOVEL PHTHALAZINONE-PYRROLOPYRIMIDINECARBOXAMIDE DERIVATIVES
  申请人：Stengel Thomas

  公开号：US20140112945A1

  公开（公告）日：2014-04-24

  The compounds of formula (1) in which R1, R7, R8, R9, R10, R17, R18, R19, R20 and m have the meanings as given in the description, are novel effective inhibitors of type 4 and type 5 phosphodiesterase.

  式（1）中的化合物，其中R1、R7、R8、R9、R10、R17、R18、R19、R20和m的含义如描述中所述，是新颖的有效的磷酸二酯酶4型和5型抑制剂。
• PIPERIDIN-2-ONE DERIVATIVE COMPOUNDS AND DRUGS CONTAINING THESE COMPOUNDS AS THE ACTIVE INGREDIENT
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1447401A1

  公开（公告）日：2004-08-18

  A piperidin-2-one derivative compound represented by formula (I): wherein all symbols are described in the specification, or a non-toxic salt thereof. The compound represented by formula (I) inhibits activation of p38MAP kinase, and is useful for prevention and/or treatment of various inflammatory diseases, rheumatoid arthritis, osteoarthritis, arthritis, osteoporosis, autoimmune diseases, infectious diseases, sepsis, cachexia, cerebral infarction, Alzheimer's disease, asthma, chronic pulmonary inflammatory diseases, reperfusion injury, thrombosis, glomerulonephritis, diabetes, graft versus host rejection, inflammatory bowel disease, Crohn's disease, ulcerative colitis, multiple sclerosis, tumor growth and metastasis, multiple myeloma, plasma cell leukemia, Castleman's disease, atrial myxoma, psoriasis, dermatitis, gout, adult respiratory distress syndrome (ARDS), arteriosclerosis, post-percutaneous transluminal coronary angioplasty (PTCA) restenosis or pancreatitis.

  一个由公式(I)表示的哌啶-2-酮衍生物化合物： 其中所有符号都在说明书中描述，或其无毒盐。 由公式(I)表示的化合物能抑制p38MAP激酶的激活，并且可用于预防或治疗各种炎症性疾病、类风湿性关节炎、骨关节炎、关节炎、骨质疏松症、自身免疫病、感染性疾病、败血症、恶病质、脑梗塞、阿尔茨海默病、哮喘、慢性肺泡炎、再灌注损伤、血栓形成、肾小球肾炎、糖尿病、移植物抗宿主病、炎症性肠病、克罗恩病、溃疡性结肠炎、多发性硬化症、肿瘤生长和转移、多发性骨髓瘤、浆细胞白血病、卡斯尔曼病、心房粘液瘤、银屑病、皮炎、痛风、成人呼吸窘迫综合征（ARDS）、动脉硬化、经皮腔内冠状动脉成形术（PTCA）后再狭窄或胰腺炎。
• [EN] NOVEL EP2 RECEPTOR AGONISTS<br/>[FR] NOUVEAUX AGONISTES DU RÉCEPTEUR EP2
  申请人：TAKEDA GMBH

  公开号：WO2013164326A1

  公开（公告）日：2013-11-07

  The compounds of formula (1), in which R1, R4, A and X have the meanings as given in the description, are novel effective EP2 agonists.

  式（1）中的化合物，其中R1、R4、A和X的含义如描述中所述，是新颖有效的EP2激动剂。
• ETHYNYLINDOLE COMPOUNDS
  申请人：OHMOTO Kazuyuki

  公开号：US20100160647A1

  公开（公告）日：2010-06-24

  As a compound having a potent oral activity and a long-lasting cysLT 1 /cysLT 2 receptor antagonistic activity, the compound of the formula (I): which exhibits potent antagonistic activity against the cysLT 1 /cysLT 2 receptor, and have long-lasting effects even in case of oral administration, and therefore is useful as an oral agent for preventing and/or treating a variety of diseases, for example, respiratory disease (for example, asthma (bronchial asthma, etc.), chronic obstructive pulmonary disease (COPD), pulmonary emphysema, chronic bronchitis, pneumonia (interstitial pneumonia, etc.), severe acute respiratory syndrome (SARS), acute respiratory distress syndrome (ARDS), apnea syndrome, allergic rhinitis, sinusitis (acute sinusitis, chronic sinusitis, etc.), pulmonary fibrosis, coughing (chronic coughing, etc.), and the like) was developed.

  作为一种具有强效口服活性和长效cysLT1/cysLT2受体拮抗活性的化合物，具有公式(I)的化合物表现出对cysLT1/cysLT2受体的强效拮抗活性，并且即使口服后也具有长效作用，因此可用作口服药剂预防和/或治疗各种疾病，例如呼吸道疾病（例如哮喘（支气管哮喘等）、慢性阻塞性肺病（COPD）、肺气肿、慢性支气管炎、肺炎（间质性肺炎等）、严重急性呼吸综合征（SARS）、急性呼吸窘迫综合征（ARDS）、呼吸暂停综合征、过敏性鼻炎、鼻窦炎（急性鼻窦炎、慢性鼻窦炎等）、肺纤维化、咳嗽（慢性咳嗽等）等）。